SUPN

#1841
Supernus Pharmaceuticals, Inc. - Common Stock
43.7 3 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
43.73
43.73
Intervallo Annuale
42.45
59.68
Variazione giornaliera
-1.04%
Variazione Mensile
-3.23%
Variazione di 6 mesi
-19.00%
Variazione Annuale
-19.02%
Chiusura Precedente
44.1 9
Open
43.7 3
Minimo
43.7 3
Massimo
43.7 3
Volume
115
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. (SUPN) covers the Annual Meeting of Stockholders held on June 14, 2024. The report details the voting results for four proposals submitted to shareholders. As of April 18, 2024, there were 54,973,754 shares of common stock outstanding and entitled to vote.

Key Financial Metrics

This filing is a corporate governance report regarding shareholder voting and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes

No material financial changes are reported in this document. The filing focuses on the outcomes of shareholder votes, including the election of directors, executive compensation approval, auditor ratification, and an amendment to the Equity Incentive Plan.

Guidance, Outlook, and Management Commentary

The filing contains no management guidance, outlook, or commentary on business risks or contingencies. It strictly reports the tabulation of votes for the following proposals:

  • Proposal 1: Election of Class III Directors (Georges Gemayel, Ph.D., and Bethany L. Sensenig) was approved with significant majority support.
  • Proposal 2: Non-binding approval of named executive officer compensation was approved.
  • Proposal 3: Ratification of KPMG LLP as the independent public accounting firm for the fiscal year ending December 31, 2024, was approved.
  • Proposal 4: Amendment to the 2021 Equity Incentive Plan to increase available shares and make technical updates was approved.

Important Facts for Investors to Verify

  • Verify the specific number of shares authorized under the amended 2021 Equity Incentive Plan, as the filing confirms the amendment passed but does not state the new share count.
  • Review the definitive proxy statement filed on April 29, 2024, for detailed biographies of the newly elected directors and the rationale for the executive compensation package.
  • Confirm the company's current financial position and cash runway through the most recent 10-Q or 10-K filing, as this 8-K contains no financial data.

Notizie